2nd time’s the charm? Novo Nordisk reups bid for high-dose Ozempic after March FDA snub
Novo Nordisk is back for round two with a new Ozempic dosing regimen. The diabetes specialist resubmitted to the FDA on Friday after a March snub, renewing its bid to compete with Eli Lilly’s already approved higher dose. Novo’s resubmission aims to nab an approval for a once-weekly, 2-mg dose for Ozempic, a GLP-1 drug already approved for weekly dosing at… Read More »